Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.81 |
| ▸ | RHOC | P08134 | 6/20 | 0.56 |
| ▸ | RHOA | P61586 | 6/20 | 0.56 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8300981 | 1.00 | TACR1 (0.81) | TACR1RHOCRHOATACR3 | |
| SCHEMBL4556039 | 1.00 | TACR1 (0.81) | TACR1RHOCRHOATACR3 | |
| SCHEMBL8291732 | 1.00 | TACR1 (0.81) | TACR1RHOCRHOATACR3 | |
| SCHEMBL8297226 | 0.89 | TACR1 (1.00) | TACR1RHOCRHOATACR3 | |
| SCHEMBL7459083 | 0.89 | TACR1 (1.00) | TACR1RHOCRHOATACR3 | |
| SCHEMBL8499946 | 0.88 | TACR1 (0.62) | TACR1RHOCRHOATACR3 | |
| SCHEMBL8296860 | 0.86 | TACR1 (0.75) | TACR1RHOCRHOATACR3 | |
| SCHEMBL7614360 | 0.85 | TACR1 (0.71) | TACR1RHOCRHOATACR3 | |
| SCHEMBL7614357 | 0.85 | TACR1 (0.71) | TACR1RHOCRHOATACR3 | |
| SCHEMBL8500550 | 0.85 | TACR1 (0.71) | TACR1RHOCRHOATACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193218-B2 | Aroyl-piperidine derivatives and method of treating disorders induced by substance P | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100120852-A1 | AROYL-PIPERIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS INDUCED BY SUBSTANCE P | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-7678814-B2 | Aroyl-piperidine derivatives | NOVARTIS AG (CH) | 2010-03-16 | — | — | US | disclosed |
| US-20060135558-A1 | Aroyl-piperidine derivatives | NOVARTIS AG (CH) | 2006-06-22 | — | — | US | disclosed |
| EP-1539737-A1 | AROYL-PIPERIDINE DERIVATIVES | Novartis AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024714-A1 | AROYL-PIPERIDINE DERIVATIVES | NOVARTIS AG (CH) | 2004-03-25 | — | — | WO | disclosed |
| EP-0739892-B1 | Chromone derivatives | NOVARTIS AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| EP-0783490-B1 | 1-ACYL-4-ALIPHATIC AMINOPIPERIDINE COMPOUNDS | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | disclosed |
| US-5965562-A | TREATING DISORDERS INDUCED BY SUBSTANCE P AND MIGRAINE HEADACHE | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5935951-A | ANTAGONIST AGAINST SUBSTANCE P | NOVARTIS FINANCE CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0707006-B1 | Aroyl-piperidine derivatives | NOVARTIS AG (CH) | 1999-04-07 | — | — | EP | disclosed |
| EP-0783490-A1 | 1-ACYL-4-ALIPHATYLAMINOPIPERIDINE COMPOUNDS | Novartis AG (CH) | 1997-07-16 | — | — | EP | disclosed |
| US-5604247-A | NEUROKININE ANTAGONIST | CIBA-GEIGY CORPORATION (US) | 1997-02-18 | — | — | US | disclosed |
| EP-0739892-A2 | Chromone derivatives | CIBA-GEIGY AG (CH) | 1996-10-30 | — | — | EP | disclosed |
| EP-0707006-A1 | Aroyl-piperidine derivatives | CIBA-GEIGY AG (CH) | 1996-04-17 | — | — | EP | disclosed |
| WO-1996010562-A1 | 1-ACYL-4-ALIPHATYLAMINOPIPERIDINE COMPOUNDS | NOVARTIS AG (CH) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135558-A1 | Aroyl-piperidine derivatives | NQO2, P2RX5, P2RX4 | TACR1 68/4885RHOC 3435/4885RHOA 4348/4885 |
| US-20100120852-A1 | AROYL-PIPERIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS INDUCED BY SUBSTANCE P | TACR1, OPRK1, OPRD1 | TACR1 1/4885RHOC 1954/4885RHOA 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.